BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: de Oliveira SM, Martins LVDO, Lupino-assad AP, Medeiros-ribeiro AC, de Moraes DA, Del-rio APT, Oliveira MC, Sampaio-barros PD, Kayser C. Severity and mortality of COVID-19 in patients with systemic sclerosis: a Brazilian multicenter study. Seminars in Arthritis and Rheumatism 2022. [DOI: 10.1016/j.semarthrit.2022.151987] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet 2023;401:304-18. [PMID: 36442487 DOI: 10.1016/S0140-6736(22)01692-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Xu L, Wang F, Luo F. Rituximab for the treatment of connective tissue disease–associated interstitial lung disease: A systematic review and meta-analysis. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1019915] [Reference Citation Analysis]
3 Keppeke GD, Satoh M, Kayser C, Matos P, Hasegawa T, Tanaka S, Diogenes L, Amaral RQ, Rodrigues S, Andrade LEC. A cell-based assay for detection of anti-fibrillarin autoantibodies with performance equivalent to immunoprecipitation. Front Immunol 2022;13:1011110. [DOI: 10.3389/fimmu.2022.1011110] [Reference Citation Analysis]
4 Keppeke GD, Satoh M, Kayser C, Matos P, Hasegawa T, Tanaka S, Santos LD, Amaral RQ, Rodrigues SH, Coelho Andrade LE. A Cell-Based Assay for Detection of Anti-Fibrillarin Autoantibodies in Systemic Sclerosis.. [DOI: 10.1101/2022.06.07.22276113] [Reference Citation Analysis]